We are live on ! Find out more
CCM

Cutter Capital Management Portfolio holdings

AUM $230M
1-Year Est. Return 11.53%
This Fund
S&P 500
This Quarter Est. Return
+2.73%
1 Year Est. Return
+11.53%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$262M
AUM Growth
+$52.4M
Cap. Flow
+$58.8M
Cap. Flow %
22.5%
Top 10 Hldgs %
57.88%
Holding
36
New
13
Increased
9
Reduced
4
Closed
10

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$20.4M
2
BMY icon
Bristol-Myers Squibb
BMY
+$15.6M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$15.6M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$13.8M
5
BIIB icon
Biogen
BIIB
+$12.2M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$16.5M
2
MRK icon
Merck
MRK
+$14.8M
3
FOLD
Amicus Therapeutics
FOLD
+$13.4M
4
ROIV icon
Roivant Sciences
ROIV
+$11.2M
5
PFE icon
Pfizer
PFE
+$7.63M

Sector Composition

Rank Sector Weight
1 Healthcare 99.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRWD icon
26
CALL
Ironwood Pharmaceuticals
IRWD
$683M
$2.18M 0.83%
+250,000
New +$3.03M
AMGN icon
27
Amgen
AMGN
$220B
– –
-57,381
Closed -$16.5M
APLS
28
DELISTED
Apellis Pharmaceuticals
APLS
– –
-108,000
Closed -$6.46M
BBIO icon
29
BridgeBio Pharma
BBIO
$16.1B
– –
-103,324
Closed -$4.17M
FOLD
30
DELISTED
Amicus Therapeutics
FOLD
– –
-947,418
Closed -$13.4M
IOVA icon
31
Iovance Biotherapeutics
IOVA
$1.94B
– –
-677,350
Closed -$5.51M
MRK icon
32
Merck
MRK
$317B
– –
-136,098
Closed -$14.8M
PBH icon
33
Prestige Consumer Healthcare
PBH
$2.51B
– –
-85,000
Closed -$5.2M
PFE icon
34
Pfizer
PFE
$147B
– –
-265,000
Closed -$7.63M
RCUS icon
35
Arcus Biosciences
RCUS
$3.48B
– –
-192,667
Closed -$3.68M
ROIV icon
36
Roivant Sciences
ROIV
$25B
– –
-1,000,000
Closed -$11.2M
1
2

Similar funds

SAM
Selway Asset Management $242M AUM 7.7% 1-Year Est. Return
CW
Cook Wealth Raleigh, North Carolina $206M AUM 4.73% 1-Year Est. Return
IAM
Impact Asset Management Vienna $255M AUM
BCM
BluePointe Capital Management Menlo Park, California $262M AUM 9.24% 1-Year Est. Return
CWM
Cahill Wealth Management Portage, Michigan $196M AUM 8.5% 1-Year Est. Return
RI
Redwood Investments Boston, Massachusetts $267M AUM 11.99% 1-Year Est. Return
LA
Lane & Associates Moorestown, New Jersey $186M AUM 5.34% 1-Year Est. Return
GWA
GGM Wealth Advisors Baltimore, Maryland $180M AUM 10.57% 1-Year Est. Return

Cutter Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Cutter Capital Management held 36 positions worth $262M, up 25% from $209M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Cutter Capital Management deployed $58.8M of net new capital in Q1 2024, opening 13 new positions and adding to 9 existing holdings. Its largest new stake was Gilead Sciences: 265,436 shares worth $19.4M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Insmed, an estimated $5.21M trimmed.

  • Cutter Capital Management's largest Q1 2024 buy was Gilead Sciences: 265,436 shares worth $19.4M.
  • Cutter Capital Management added most to Bristol-Myers Squibb in Q1 2024, an estimated $15.6M increase.
  • Cutter Capital Management's biggest Q1 2024 reduction was Insmed, cutting an estimated $5.21M.
  • Cutter Capital Management fully exited Amgen in Q1 2024, selling an estimated $16.5M.
  • Cutter Capital Management's ten largest holdings make up 58% of its $262M portfolio in Q1 2024.
  • Cutter Capital Management opened 13 new positions and closed 10 in Q1 2024.
  • Cutter Capital Management's portfolio value rose 25% quarter-over-quarter to $262M.

Based on Cutter Capital Management's 13F filing for Q1 2024, filed 15 May 2024.